Nitroglycerin Transdermal Delivery System Features Key Packaging Features

The generic pharmaceutical company Alvogen Inc. (Parsippany, N.J.) introduces the AB-1 rated Nitroglycerin Transdermal Delivery System, which is available in patient-ready, 30-count cartons and includes several key packaging features designed to improve care. Some of these features are RSS barcoding on each individual unit; the smallest available patch sizes of any generic nitroglycerin system; and hypoallergenic, transparent patches.

“Alvogen is pleased to introduce this transdermal system as part of our U.S. product portfolio,” says Doug Drysdale, CEO, Alvogen. “This product is a definitive example of our focus to provide limited source, complex generic drugs that include added-value packaging characteristics for our customers and patients.”

The nitroglycerin transdermal delivery system is indicated for the prevention of angina pectoris due to coronary artery disease. The onset of action of transdermal nitroglycerin is not sufficiently rapid for this product to be useful in aborting an acute attack. The Alvogen nitroglycerin system is immediately available in four dosage strengths, including 0.1, 0.2, 0.4, 0.6 mg/hr.